Please login to the form below

Not currently logged in

Advodart with tamsulosin reduces AUR risk

Data shows that GSK's Avodart and tamsulosin combination treatment reduces the risk of acute urinary retention

Final results from the four-year GlaxoSmithKline (GSK)-sponsored Combination therapy with Avodart and tamsulosin (CombAT) study show that GSK's Avodart (dutasteride) and tamsulosin combination treatment reduces the risk of acute urinary retention (AUR) or Benign Prostatic Hyperplasia (BPH)-related surgery, as well as reduced the risk of BPH clinical progression more than tamsulosin alone. Combination treatment also delivered superior, sustained symptom improvement from month nine compared to either dutasteride or tamsulosin monotherapy. 

A 66 per cent reduction in the risk of AUR or BPH-related surgery was achieved with combination treatment compared to tamsulosin (p<0.001) and there was a 20 per cent reduction compared to dutasteride (p=0.18). The risk of BPH clinical progression with combination treatment was reduced by 44 per cent, compared to tamsulosin and 31 per cent for those on dutasteride. 

The combination therapy was generally well tolerated, with erectile dysfunction and retrograde ejaculation the most commonly reported drug-related adverse events. The incidence of heart failure was however higher in the combination (0.9 per cent) and tamsulosin (0.6 per cent) than in the dutasteride group (0.2 per cent). There was no difference in overall cardiovascular events across treatment groups. 

Affecting 50 per cent of men over 50 years old, BPH is not life-threatening, but if left untreated, can lead to AUR, a complete obstruction of urinary excretion and BPH-related surgery.

12th October 2009


Featured jobs

Subscribe to our email news alerts


Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

A quest for innovative solutions
UCB looks to the future through a PRISM...
Big data, privacy and the rise of genomic testing
Blue Latitude Health speaks to Johan Christiaanse, Marketing Director at BGI, to find out how the medical profession can overcome one of the major barriers to precision medicine – big...
Deal Watch January 2018